Paul Tran

Summary

Affiliation: Harvard School of Public Health
Country: USA

Publications

  1. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
  2. pmc Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
  3. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
  4. ncbi request reprint Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
  5. ncbi request reprint Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
  6. ncbi request reprint Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
  7. pmc Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
  8. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011

Collaborators

  • Gonzague Jourdain
  • Marc Lallemant
  • Mark Mirochnick
  • Nicole Ngo-Giang-Huong
  • Pilaipan Puthavathana
  • Thanyawee Puthanakit
  • Nottasorn Plipat
  • Sombat Thanprasertsuk
  • Jean Marc Treluyer
  • Saik Urien
  • K Chokephaibulkit
  • L M Frenkel
  • Maureen Shannon
  • Deborah Hirt
  • Tim R Cressey
  • Chureeratana Bowonwatanuwong
  • Sinart Prommas
  • Prapap Yuthavisuthi
  • Yardpiron Taworn
  • Prakit Yothipitak
  • Kanchana Than-in-at
  • Dujrudee Chinwong
  • Renoo Wongsrisai
  • Suriyan Tanasri
  • Pra ornsuda Sukrakanchana
  • Patcharaporn Krueduangkam
  • Suporn Koetsawang
  • Elizabeth Smith
  • Luc Decker
  • Borwornluck Changlor
  • Tiwacha Thimakam
  • Sanupong Chailert
  • Ruethai Wongchai
  • Ken McIntosh
  • Suwalai Chalermpantmetagul
  • Kanjana Yoddee
  • Sophie Le Coeur
  • Aksorn Lueanyod
  • Pimpinun Punyati
  • Somrat Matchua
  • Pisut Greetanukroh
  • Nantasak Chotivanich
  • Kessarin Chaisiri
  • Nusara Krapunpongsakul
  • Jullapong Achalapong
  • Marina Thitathan
  • Janjira Thonglo
  • Ubon Chanasit
  • Edmund Capparelli
  • Michel Tod
  • Prattana Leenasirimakul
  • Suparat Kunkeaw
  • Chanon Neungton
  • Brookie M Best
  • Pannee Sirivatanapa
  • Yanling Huo
  • Alice Stek
  • Supawadee Tongsakulrungruang
  • Intira Collins
  • Orapin Khatngam
  • Suppanut Khannak Jiradsadaporn Khanmali
  • Praornsuda Sukrakanchana
  • Praneet Pinklow
  • Sirinat Toyang
  • Anchalee Singkaew
  • Den Roumsuk
  • Malee Techapornroong
  • Guttiga Halue
  • Prateep Kanjanavikai
  • Kunlaya Jansook
  • Somsong Niamlamul
  • Chutima Seema
  • Aram Limtrakul
  • Rungruangrong Seubmongkolchai
  • Nuttharee Pinkaew
  • Wanpen Leelaporn
  • Nuttupassasorn Tungtongcha
  • Sudtida Eawsakul
  • Sukonta Phasuk
  • Tapnarong Jarupanich
  • Purivis Chart
  • Waropart Pongchaisit
  • Yaowalak Sookbumrung
  • Pongpreeda Saenchitta
  • Supaporn Utsaha
  • Rucha Kongpanichkul
  • Phithak Kaeha
  • Jittapol Hemvuttiphan
  • Kingtong Wongsirikul
  • Sinnapa Pothinukka

Detail Information

Publications8

  1. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  2. pmc Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
    ..The impact of pregnancy on efavirenz (EFV) pharmacokinetics is unknown...
  3. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...
  4. ncbi request reprint Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
    ..To assess the steady-state pharmacokinetics of two reduced doses of indinavir boosted with ritonavir (indinavir/ritonavir) in HIV-infected Thai patients...
  5. ncbi request reprint Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
    ....
  6. ncbi request reprint Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
    ..Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited. Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings...
  7. pmc Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
    ....
  8. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011
    ..The risk of toxic drug concentrations increases rapidly with IDV/r dose of 600/100 mg for patients less than 50 kg and therapeutic drug monitoring of IDV concentrations would help to reduce the risk of IDV-induced nephrotoxicity...